Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
This article was originally published in The Tan Sheet
Executive Summary
Perrigo stokes momentum behind already healthy sales growth with significant steps in separate areas: a green light for regulatory compliance at its main manufacturing plant, and the launch of its generic OTC versions of Sanofi-Aventis' Allegra.
You may also be interested in...
Allegra Brand Revision Will Sell Romance, Emotion
The OTC Allegra package branding when launched in March 2011 was limited by FDA until after the product lost market exclusivity, consultant Terri Goldstein says. Loss of market exclusivity opened the door to make Allegra branding “how we wished the package could have looked,” she says.
Allegra Brand Revision Will Sell Romance, Emotion
The OTC Allegra package branding when launched in March 2011 was limited by FDA until after the product lost market exclusivity, consultant Terri Goldstein says. Loss of market exclusivity opened the door to make Allegra branding “how we wished the package could have looked,” she says.
Perrigo Relies On New Products For Fiscal Second-Half Boost
Planned launches of generic Claritin-D, Mucinex and Prevacid 24HR are expected to help Perrigo reach 12% to 14% consumer health care growth in fiscal 2012. Opportunities to gain from J&J and Novartis OTC recalls likely are minimal going forward, the private labeler says on its Q2 earnings call.